Introduction
Copy number variation (CNV) refers to the difference in the dosage of genomic segments, ranging in size from one kilobase (kb) to several megabases (Mb), when compared to a reference human genome. CNVs can result from structural variations within the genome including deletions, duplications, insertions, or unbalanced translocations and inversions, which can lead to either a loss or gain of genomic segments. CNVs are widespread within the genomes of healthy individuals with no apparent association to disease phenotypes [1•, 2•, 3, 4, 5•, 6, 7, 8, 9] . The systematic analysis of CNVs in large populations of healthy individuals has begun to reveal the frequency and the effect of this variation in the human genome [10, 11] . CNVs account for more of the inter-individual variability between genomes in terms of total number of bases involved than all the single nucleotide variations (SNVs) and small insertion-deletions (indels), combined [12•, 13] .
Despite the existence of apparently benign CNVs in the human genome, numerous CNVs have been implicated in the etiology of a wide variety of human diseases including intellectual disability (ID), multiple congenital anomaly syndromes, as well as complex neurodegenerative and neuropsychiatric disorders, cancer, and immune deficiency [14, 15] . The availability and application of increasingly higher resolution genomic technologies, especially in clinical diagnostics, has greatly improved the detection of CNVs and has led to the discovery of new CNV disorders. Thus, CNVs have become increasingly recognized as a significant source not only of genetic diversity within the general population but also the mutational burden associated with human disease. This review will focus on genetic disorders arising from CNVs, the mechanisms by which CNVs can lead to disease; the underlying genomic rearrangements associated with both recurrent and non-recurrent CNVs and the advantages and limitations of current and emerging methodologies used in CNV detection and the challenges that remain in the association of CNVs to disease.
Genetic Disorders Arising from CNVs CNVs Associated with Genomic Disorders
CNVs such as microdeletions and microduplications have long been recognized as a source of mutation in well-characterized genetic disorders and syndromes. These CNV disorders result from genomic alterations or rearrangements mediated by unstable genomic architecture, and are also referred to as genomic disorders [16] . A few of the well-characterized CNV disorders include Prader-Willi and Angelman syndromes (PWS/AS) [17] , which result from microdeletions in 15q11-q13; WilliamsBeuren syndrome (WBS) [18] , which results from microdeletions in 7q11.23 and the 22q11.2 deletion syndrome (22q11.2 DS, previously referred to as DiGeorge/ Velocardiofacial syndromes) [19] . In a majority of the known CNV disorders, affected individuals usually present with multiple congenital anomalies (MCA) including intellectual disability (ID), developmental delay (DD), dysmorphic features, cardiac defects, limb and digital abnormalities, and seizures [20] . Most of these disorders were initially recognized due to a set of overlapping phenotypic features observed in a majority of the affected individuals. Subsequent genetic testing using targeted tests such as fluorescence in situ hybridization (FISH) were then used to confirm association of the phenotype with specific microdeletions or microduplications.
Over the past several years, the increased application of microarray-based CNV analysis in clinical diagnostics has led to an explosion in the number of genomic disorders and syndromes that have been directly associated with microdeletions and/or microduplications [20] . Many new microdeletion and microduplication syndromes associated with 1q21.1 [21] , 16p11.2 [21] , and 15q13.3 [22] have been described (Table 1) . The ever-expanding list of these types of novel CNV disorders as well as rare, one-off CNVs associated with disease phenotypes, underscores the significance of CNV-based mutations in genetic disorders. Not surprisingly, a majority of these newly described CNV disorders are also associated with MCA and ID/DD (Table 1) .
CNVs Associated with Common Complex Diseases
CNVs have also been associated with the etiology of complex, neuropsychiatric diseases including autism spectrum disorders (ASD) and schizophrenia (SZ CNVs have also been associated with neurodegenerative disorders including Parkinson disease (PD) and Alzheimer disease (AD). In addition to duplications and triplications of the asynuclein gene locus in patients with PD [45, 46] , recent studies have suggested that CNVs may increase the risk for PD [47, 48] . Copy number gains of APP due to trisomy 21 in Down syndrome or through microduplications are associated with earlyonset familial AD [49] . CNV studies in patients with AD have detected enrichment of CNVs affecting dosage-sensitive, brainspecific genes [50] . Furthermore, multiallelic CNVs that occur at high frequencies (> 1%) in the population have been associated with several complex diseases or traits including susceptibility to HIV infection, autoimmune diseases like systemic lupus erythromatosus (SLE), rheumatoid arthiritis (RA), Crohn's disease, type 2 diabetes, and obesity as well as roles in drug metabolism and toxicity [15] .
CNVs involving some genes like the β-defensin cluster on 8p23.1 have been associated with multiple diseases including Crohn's disease and several skin disorders including psoriasis, hidradenitis suppurativa/acne inversa [51] , and dermatophytosis [52] . Similarly, CNVs of the Fc gamma receptor (FCGR) gene cluster on 1q23.3 have been associated with SLE [53] , RA [54] , and many other autoimmune disorders. However, many of these CNV associations have failed to replicate, especially in nonEuropean populations [55] . It is believed that the lack of replication may be at least partially related to the limitations in the techniques used to assess copy number of these genes and the complex duplicated architecture of the genomic regions they are located within [15, 56] . Thus, the application of reliable and standard genotyping techniques to large cohorts will be necessary to assess the true association of multiallelic CNVs to complex diseases and traits.
Mechanisms of Disease Pathogenesis in CNV Disorders
CNVs can lead to a disease phenotype by a variety of mechanisms based upon their size, location, and gene content. The alteration in the copy number of one or more dosage-sensitive genes, encompassed within a large microdeletion or microduplication, is the most common mechanism underlying CNV-mediated disease pathogenesis. This is expected to be the mechanism for disease pathogenesis in most CNV disorders including the 22q11.2 DS, WBS, PWS/AS, CharcotMarie Tooth disease type 1A/Hereditary Neuropathy with Pressure Palsies (CMT1A/HNPP), and Sotos syndrome [16] [17] [18] [19] [20] . Alternatively, an intragenic CNV may have the same effect as a disruptive point mutation, effectively inactivating the gene and leading to haploinsufficiency. Indeed, exonic or multiexonic CNVs within dosage-sensitive genes represent a significant percentage of mutations in monogenetic disorders [57, 58] .
CNVs may also alter the expression of genes that are upstream or downstream of the CNV by disrupting regulatory elements like enhancers or promoters [59, 60] . A 20-kb deletion which is 2.7 kb upstream of IRGM is associated with altered expression of the gene leading to Crohn's disease [61] ). Similarly, a 47-kb deletion downstream of SHOX, which removes and enhancer element, has been associated with skeletal dysplasia and short stature [62] . CNVs may also reveal recessive disorders, wherein a deletion of one allele of the gene unmasks a point mutation on the other allele, resulting in disease. For example, in three individuals with unexplained intellectual disabilities, the discovery of a CNV that deleted the COH1 gene led to the subsequent identification of a second pathogenic point mutation in COH1, leading to a diagnosis of Cohen syndrome, an autosomal recessive disorder [63] . Deletions of the non-mutated allele of IL7R have been uncovered by retrospective analysis of patients with autosomal recessive T−B+NK+ severe combined immunodeficiency (SCID), with a mutation previously detected in only one allele [64] .
Mechanisms of CNV Formation
CNVs associated with genetic disorders are classified as either recurrent or unique (non-recurrent) based on the rearrangement mechanisms underlying their formation. Recurrent CNVs are usually flanked by segmental duplications (SDs) or low copy number repeats (LCRs) [65] . Segmental duplications (SDs) are repetitive sequences in the human genome that are defined as being ≥ 1 kilobase (kb) in size and whose copies or paralogs share ≥ 90% sequence identity with each other and are estimated to account for approximately 5% of the human genome [66] . SDs associated with CNV disorders are often > 100 kb, with a complex organization of duplicated modules that may share 96-99% sequence identity with paralogous copies [16] [17] [18] [19] [20] . The high level sequence identity shared by paralogous SDs can lead to misalignment between non-allelic SDs on homologous chromosomes. Subsequent recombination between the misaligned SDs can result in the formation of reciprocal deletion and duplication CNVs. This mechanism referred to as non-allelic homologous recombination (NAHR) Refs, references; ID, intellectual disability; DD, developmental delay; MCA, multiple congenital anomalies; del, microdeletion; dup, microduplication is known to mediate genomic rearrangements associated with several genetic syndromes [16] . The presence of SDs flanking the genomic regions associated with several known syndromes implicated SD-mediated NAHR in the formation of CNVs associated with Prader-Willi syndrome (PWS)/Angelman syndrome (AS) [17] , WilliamsBeuren syndrome (WBS) [18] , DiGeorge syndrome (DGS)/ velocardiofacial syndrome (VCFS) [and now collectively referred to as the 22q11.2 deletion syndrome (22q11.2DS) 19], and Smith-Magenis (SMS)/Potocki-Lupski syndromes [67] . Based on these findings and the large number of SDs identified in the human genome suggested that SD-mediated NAHR could be associated with additional, yet unidentified disorders [68, 69•] . Indeed, the number of SD-mediated genomic disorders has expanded with the discovery of novel disorders [20] .
The mechanisms underlying the formation of non-recurrent CNVs are not as well understood. Recent analyses of breakpoints in several non-recurrent CNVs have suggested the involvement of non-homologous end joining (NHEJ) and replication-based mechanisms (RBMs) [16, 70, 71] . NHEJ is a mechanism by which double-stranded breaks (DSBs) are repaired in organisms ranging from bacteria to mammals [72] [73] [74] . NHEJ does not require sequence homology to mediate recombination. However, the presence of SDs or other repetitive DNA elements appear to stimulate NHEJmediated rearrangements associated with CNV formation [14, 16] . The application of higher resolution techniques in the analysis of CNV breakpoints has suggested that mechanisms other NAHR or NHEJ may be involved in their formation [70, 71] . This led to the proposal of RBMs, including breakinduced replication (BIR), fork stalling and template switching (FoSTeS), and microhomology-mediated break-induced replication (MMBIR) [16, 71] . RBMs are also likely to be stimulated by SDs and other repetitive DNA elements that promote the formation of unstable secondary structures, which can then lead to replication fork stalling or collapse leading to DNA breakage. The subsequent replicative repair of the broken DNA can lead to the formation of deletions, duplications, and other rearrangements [16] . RBM-based mechanisms have been proposed in the formation of several non-recurrent CNVs including duplications of Xq28 including MECP2 [16, 71] .
The Evolution of CNV Detection Methods
The technologies used for CNV detection have rapidly evolved in recent years. In the past, cytogenetic analysis by karyotyping allowed the detection of CNVs > 10 Mb, in addition to aneuploidies and gross chromosomal rearrangements like translocations and inversions. However, the detection of CNVs < 10 Mb required targeted, low-throughput methods like fluorescence in situ hybridization (FISH) and real-time PCR [75, 76] , or medium throughput techniques such as multiplex amplifiable probe hybridization [77] . A number of technologies can detect copy number gains and losses throughout the human genome and their resolution is continuously increasing. The advent of genome-wide assays using highdensity microarrays [78] greatly enhanced our ability to detect CNVs at an unprecedented resolution.
High-resolution microarray-based CNV analysis provided a method to detect microdeletions and microduplications as well as novel CNVs that are undetectable by standard karyoptye analysis or FISH [79] . CNV analysis using arraybased comparative genomic hybridization (aCGH) or single nucleotide polymorphism (SNP)-based microarrays (SNParrays) provide efficient tools for researchers and clinicians. CNV microarrays can also detect low-level mosaicism, which would be missed by traditional methods used in cytogenetics [80, 81] . Furthermore, SNP-arrays provide genotype information that can be used to identify genomic regions with copy number neutral, loss of heterozygosity (LOH), which usually result from uniparental disomy (UPD) or parent of common origin effects [82, 83] . Exon-focused CNV microarrays have been designed to allow the detection of exonic CNVs in targeted or genome-wide assays, since a significant number of mutations in monogenetic disorders involve intragenic CNVs that affect one or a few exons of a gene [57, 58, 84] .
Thus, CNV microarrays have significantly increased diagnostic yield in genetic disorders, leading to their adoption by clinical laboratories as the first tier of testing for individuals with nonsyndromic intellectual disability (ID), autism spectrum disorders (ASD), and multiple congenital anomalies (MCA) [78, 79] . Consequently, the identification of an underlying genetic etiology in patients with ID, ASD, and MCA has significantly increased due to the application of CNV microarrays [20, 85] . The impact of establishing a genetic diagnosis in congenital disorders is significant as it allows appropriate referrals for therapy and surveillance for potential future involvement of other tissues and organs, and assists in better genetic counseling for the family [79] . With the increased application of CNV analysis on large patient cohorts, novel microdeletion and microduplication have been identified and associated with disease phenotypes [86•] . CNV detection using microarrays remains the current mainstay of the clinical cytogenetic laboratory [78, 79] .
High-throughput sequencing (HTS) technologies are becoming more routine tools for the analysis of genetic variation in the human genome. The ability to detect all forms of genetic variation including single nucleotide variations (SNVs), small (< 50 bp) insertions/deletions (InDels), CNVs, and copy neutral structural variations on a single platform make HTS highly desirable in clinical diagnostics. The use of whole exome sequencing (WES) for the detection of exonic mutations in patients with Mendelian disorders has seen a rapid rise in clinical diagnostics [87] . Several algorithms have been developed to identify CNVs from WES data, most of which use readdepth-based approaches for the detection of changes in copy number [88] . However, several limitations both, of WES methodology as well as the algorithms for CNV detection from WES data, prevent the reliable application of WES-based CNV detection in the clinical laboratory [89, 90] . Whole genome sequencing (WGS) and analysis pipelines developed for variation detection have become increasingly robust over the past several years enabling the detection of thousands of novel CNVs and other structural variations [10, 11, 12•] . Furthermore, the recent application of novel, long-read sequencing [91] and genome mapping [92] technologies have greatly enhanced the discovery of structural and copy number variations in whole-genome assays. Thus, the ongoing development and application of novel, high-throughput sequencing and mapping technologies holds great promise for the comprehensive detection of all forms of variation, especially CNVs, which will likely increase the diagnostic yield in patient cohorts.
Challenges in CNV Association to Disease
CNV analysis with microarrays is offered as routine clinical test, with the results being increasingly used in genetic counseling and clinical management [85] . However, the ability to detect CNVs using high-throughput technologies has far outpaced the ability to determine their role in disease pathogenesis. A majority of the microarrays used in clinical laboratories are designed to have a high density of probes to allow for maximum resolution for the capture of CNVs genome-wide. An inadvertent outcome of this improved detection has been the increase in the detection of CNVs that are of unknown clinical significance. This is mainly because the interpretation of novel CNVs is difficult, leading to wide variability in assessment and reporting of the clinical significance of CNVs by different diagnostic laboratories [79] . Some guidelines that allow better interpretation of the clinical significance or disease association of CNVs include criteria such as overlap with known contiguous gene syndromes, CNV size and gene content, whether the CNV is de novo or inherited, and comparison to CNV databases and medical literature [85] .
CNV data from healthy controls is available in public databases such as the Database of Genomic Variants and NCBI's Database of genomic structural variation (dbVar) (see Web Resources). Further, clinically relevant CNVs are available from databases such as DECIPHER, ECARUCA, ClinGen, and ClinVar (see Web Resources). CNV data generated from whole exome sequencing is now available in the Exome Aggregation Consortium (ExAC) database. These resources have become invaluable in discriminating pathogenic from non-disease-associated CNVs. However, once whole genome sequencing (WGS) becomes a more routine test in clinical diagnostics, additional databases of CNVs detected by WGS will be required.
Conclusions
The role of CNVs in human disease as well as normal genetic variation has become increasingly apparent as a result of the higher resolution analysis of the genome. However, CNVs continue to be underappreciated as a source of mutation in disease mainly due to the limitations in the accurate detection of CNVs, especially those that are smaller affect one or a few exons of a single gene, affect regulatory regions of genes, or occur within genomic regions that contain complex genomic architecture, like segmental duplications. Furthermore, in order to associate CNVs with disease will require larger databases with CNV data from control samples analyzed using equivalent high-resolution techniques. This appreciation of the limitations of current technology and resources for the detection and disease association of CNVs has been critical in providing the impetus towards developing newer technologies and better data resources for a truly comprehensive analysis of all forms of variation within the human genome.
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